HARRISON J. SHULL Jr., M.D.; GRANT R. WILKINSON, Ph.D.; RAYMOND JOHNSON; STEVEN SCHENKER, M.D.
Oxazepam (Serax®) is a tranquilizer-sedative of the benzodiazepine group that is predominantly metabolized to a pharmacologically inactive glucuronide and subsequently excreted by way of the kidneys. We administered this drug as a single oral dose to seven patients with acute viral hepatitis, to six with cirrhosis, and to age-matched control subjects. Elimination half-life (T½) and the apparent oral plasma clearance for the drug in patients with hepatitis and cirrhosis were comparable to values obtained in age-matched controls (P > 0.05). In addition, the apparent volume of distribution of oxazepam, its plasma binding, blood/plasma ratio, and the rate of urinary excretion of oxazepam, predominantly as the glucuronide, were comparable (P > 0.05) in the two groups of patients with liver disease and their respective controls. Unlike many other sedatives, oxazepam is eliminated normally in patients with parenchymal liver disease and therefore, on pharmacokinetic grounds, seems to be an excellent sedative for use in such persons.
Learn more about subscription options.
Register Now for a free account.
SHULL HJ, WILKINSON GR, JOHNSON R, SCHENKER S. Normal Disposition of Oxazepam in Acute Viral Hepatitis and Cirrhosis. Ann Intern Med. 1976;84:420–425. doi: 10.7326/0003-4819-84-4-420
Download citation file:
Published: Ann Intern Med. 1976;84(4):420-425.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease, Viral Hepatitis.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only